A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer - Trial NCT06225804
Access comprehensive clinical trial information for NCT06225804 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abbisko Therapeutics Co, Ltd and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 164 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Abbisko Therapeutics Co, Ltd
Timeline & Enrollment
Phase 1
Feb 22, 2024
Mar 01, 2028
Primary Outcome
Incidence of DLT,AEs,AESIs,SAEs
Summary
This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of
 ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary
 antitumor efficacy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06225804
Non-Device Trial